Adaptimmune LLC
351 Rouse Boulevard, 19112-1903, United States
About the sponsor
Adaptimmune LLC focuses on developing innovative cellular immunotherapy approaches for cancer treatment. The company's research portfolio centers on engineered T-cell receptor (TCR) therapies designed to target specific tumor-associated antigens. Their clinical programs investigate novel mechanisms of action that enable the immune system to recognize and eliminate cancer cells with greater precision and efficacy.
- Engineered T-cell receptor therapeutics
- Targeted cancer immunotherapy
- Adoptive cell transfer strategies
The therapeutic development pipeline emphasizes personalized medicine approaches that harness the patient's own immune system, representing a significant advancement in the field of immuno-oncology and precision cancer treatment.
Try clearing a filter, or search the whole catalogue.
Are you running a clinical trial?
Increase visibility for your trials and help patients find your site through our platform.